Projects

Top Sector Life Sciences & Health (LSH) entails a broad scope of disciplines, from pharmaceuticals to medical technology and from healthcare infrastructure to vaccination. To realise its mission – vital citizens in a healthy economy - the Top Sector builds on the strengths of the Dutch LSH sector to address the biggest societal challenges in prevention, cure and care. By funding multidisciplinary public private partnerships (PPPs) the Top Sector aims to facilitate innovation. Here we give an overview of funded R&D projects by Top Sector LSH.

A new class of medicine for Ulcerative Colitis

The effects of specific kinase inhibitors in colitis models.

Inflammatory Bowel Disease (IBD) arises by excess inflammation in the gut by unknown cause. As IBD affects mostly young adults, is relatively common (80,000 patients in the Netherlands) and is a live-long condition, new treatment modalities are very much welcomed as current therapies have important shortcomings and come with high treatment costs.

Here, we have established a public-private partnership with GlaxoSmithKline's (GSK) drug development progression facilities, to develop new therapeutic options for IBD. One such novel therapy could come from inhibition of so-called Jak kinases, which are inflammatory proteins that are produced by immune cells signal to target cells via signal transduction mechanisms. More specifically, Jak1, and Tyrosine Kinase 2 (Tyk2) are involved in signalling of pro-inflammatory cytokines involved in IBD. These cytokines signals via Jak and Tyk kinases mediate their actions on inflammatory responses. Small molecule Jak inhibitors targeting Jak by inhibiting its activation are currently tested in clinical trials for various inflammatory diseases such as Rheumatoid Arthritis and (IBD). However, these molecules target large classes of Jak molecules.

In this project, the academic university hospital and referral center for IBD, the AMC, is collaborating with GSK to allow testing of newly developed small molecules inhibiting Jak kinases more specifically than current medication. Rather than general Jak inhibitors, specific Jak inhibitors were tested preclinically (at the lab and in animal models). However, Jak1 inhibitors were also tested in a small patient trial.

Our results show that a novel orally delivered specific Jak kinase inhibitor has clinical potential to reduce colitis, in preclinical (Tyk2i) and clinical (Jak1i) studies. In retrospect, our project shows the potential of private-academic collaboration in small molecule development and pharmacokinetics, and its testing in preclinical phase as well as clinical relevant patients trials. The impact of this work for society and health care is that it has allowed the clinical introduction of specific Jak kinase inhibitors in IBD, a difficult to treat condition.

See the website of the spin off company Gut Research B.V. or the IBD group website for more information about this research.